Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report
ABSTRACT We herein describe a patient with non‐small‐cell lung cancer who achieved pCR with a single dose of pembrolizumab‐based chemoimmunotherapy followed by surgery. A 61‐year‐old man was referred to our hospital with wheezing and an abnormal chest shadow. Squamous cell carcinoma of the left lowe...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15519 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576772525260800 |
|---|---|
| author | Yugo Matsumura Seiya Ichihara Kaori Nii Kazumasa Nanjo Naoki Kadota Yoshio Okano Hisanori Machida Nobuo Hatakeyama Hiroyuki Hino Keishi Naruse Tsutomu Shinohara Shoji Sakiyama Eiji Takeuchi |
| author_facet | Yugo Matsumura Seiya Ichihara Kaori Nii Kazumasa Nanjo Naoki Kadota Yoshio Okano Hisanori Machida Nobuo Hatakeyama Hiroyuki Hino Keishi Naruse Tsutomu Shinohara Shoji Sakiyama Eiji Takeuchi |
| author_sort | Yugo Matsumura |
| collection | DOAJ |
| description | ABSTRACT We herein describe a patient with non‐small‐cell lung cancer who achieved pCR with a single dose of pembrolizumab‐based chemoimmunotherapy followed by surgery. A 61‐year‐old man was referred to our hospital with wheezing and an abnormal chest shadow. Squamous cell carcinoma of the left lower lobe, cT2aN1M0 stage IIB, was diagnosed and pembrolizumab‐based chemoimmunotherapy was initiated at the patient's request. One month later, chest CT revealed new ground‐glass opacities of the lungs, which were judged to be a CTCAE grade 2 pneumonitis due to an immune‐related adverse event (irAE). Therefore, steroid therapy was initiated. Prednisolone was tapered and discontinued as symptoms improved. A sleeve resection of the left lower lobe was performed, and a pathological complete response (pCR) was confirmed in a resected specimen. There has been no recurrence for 1 year and 7 months without treatment. This is the first case report of pCR to a single dose of chemoimmunotherapy followed by surgery for lung cancer. The present results suggest the potential of a single dose of chemoimmunotherapy to achieve pCR and cause irAEs in some patients. |
| format | Article |
| id | doaj-art-9473a4fb47a9489da6238148a67985a8 |
| institution | Kabale University |
| issn | 1759-7706 1759-7714 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj-art-9473a4fb47a9489da6238148a67985a82025-01-30T22:40:34ZengWileyThoracic Cancer1759-77061759-77142025-01-01162n/an/a10.1111/1759-7714.15519Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case ReportYugo Matsumura0Seiya Ichihara1Kaori Nii2Kazumasa Nanjo3Naoki Kadota4Yoshio Okano5Hisanori Machida6Nobuo Hatakeyama7Hiroyuki Hino8Keishi Naruse9Tsutomu Shinohara10Shoji Sakiyama11Eiji Takeuchi12Department of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi City Kochi JapanDepartment of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi City Kochi JapanDepartment of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi City Kochi JapanDepartment of Thoracic Surgery National Hospital Organization Kochi Hospital Kochi City Kochi JapanDepartment of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi City Kochi JapanDepartment of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi City Kochi JapanDepartment of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi City Kochi JapanDepartment of Respiratory Medicine National Hospital Organization Kochi Hospital Kochi City Kochi JapanDepartment of Thoracic Surgery National Hospital Organization Kochi Hospital Kochi City Kochi JapanDepartment of Pathology National Hospital Organization Kochi Hospital Kochi City Kochi JapanDepartment of Community Medicine for Respirology, Graduate School of Biomedical Sciences Tokushima University Tokushima JapanDepartment of Thoracic Surgery National Hospital Organization Kochi Hospital Kochi City Kochi JapanDepartment of Clinical Investigation National Hospital Organization Kochi Hospital Kochi City Kochi JapanABSTRACT We herein describe a patient with non‐small‐cell lung cancer who achieved pCR with a single dose of pembrolizumab‐based chemoimmunotherapy followed by surgery. A 61‐year‐old man was referred to our hospital with wheezing and an abnormal chest shadow. Squamous cell carcinoma of the left lower lobe, cT2aN1M0 stage IIB, was diagnosed and pembrolizumab‐based chemoimmunotherapy was initiated at the patient's request. One month later, chest CT revealed new ground‐glass opacities of the lungs, which were judged to be a CTCAE grade 2 pneumonitis due to an immune‐related adverse event (irAE). Therefore, steroid therapy was initiated. Prednisolone was tapered and discontinued as symptoms improved. A sleeve resection of the left lower lobe was performed, and a pathological complete response (pCR) was confirmed in a resected specimen. There has been no recurrence for 1 year and 7 months without treatment. This is the first case report of pCR to a single dose of chemoimmunotherapy followed by surgery for lung cancer. The present results suggest the potential of a single dose of chemoimmunotherapy to achieve pCR and cause irAEs in some patients.https://doi.org/10.1111/1759-7714.15519immune checkpoint inhibitorsnon‐small‐cell lung cancerpathological complete responsesingle dosesquamous cell carcinoma |
| spellingShingle | Yugo Matsumura Seiya Ichihara Kaori Nii Kazumasa Nanjo Naoki Kadota Yoshio Okano Hisanori Machida Nobuo Hatakeyama Hiroyuki Hino Keishi Naruse Tsutomu Shinohara Shoji Sakiyama Eiji Takeuchi Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report Thoracic Cancer immune checkpoint inhibitors non‐small‐cell lung cancer pathological complete response single dose squamous cell carcinoma |
| title | Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report |
| title_full | Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report |
| title_fullStr | Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report |
| title_full_unstemmed | Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report |
| title_short | Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report |
| title_sort | pathological complete response to a single dose of pembrolizumab based chemoimmunotherapy for squamous cell carcinoma of the lung a case report |
| topic | immune checkpoint inhibitors non‐small‐cell lung cancer pathological complete response single dose squamous cell carcinoma |
| url | https://doi.org/10.1111/1759-7714.15519 |
| work_keys_str_mv | AT yugomatsumura pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport AT seiyaichihara pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport AT kaorinii pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport AT kazumasananjo pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport AT naokikadota pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport AT yoshiookano pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport AT hisanorimachida pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport AT nobuohatakeyama pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport AT hiroyukihino pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport AT keishinaruse pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport AT tsutomushinohara pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport AT shojisakiyama pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport AT eijitakeuchi pathologicalcompleteresponsetoasingledoseofpembrolizumabbasedchemoimmunotherapyforsquamouscellcarcinomaofthelungacasereport |